Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010

Asian Biomedicine

Volumn 4, Issue 4, 2010, Pages 515-528

  Sungkanuparph, Somnuek ^a   Techasathit, Wichai ^b   Utaipiboon, Chitlada ^c   Chasombat, Sanchai ^c   Bhakeecheep, Sorakij ^d   Leechawengwongs, Manoon ^e   Ruxrungtham, Kiat ^f,g   Phanuphak, Praphan ^f,g  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

^d National Health Security Office   (Thailand)

^e Thai Transplantation Society   (Thailand)

^f CHULALONGKORN UNIVERSITY   (Thailand)

^g THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

Adolescent; Adult; Antiretroviral; HIV; Thai guidelines

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABNORMAL DREAMING; AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATRIOVENTRICULAR BLOCK; C BANDING; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONFUSION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DYSLIPIDEMIA; FANCONI RENOTUBULAR SYNDROME; HEALTH CARE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLACTATEMIA; HYPERPIGMENTATION; HYPERTRIGLYCERIDEMIA; INSOMNIA; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; LUNG TUBERCULOSIS; MACROCYTIC ANEMIA; MIXED INFECTION; NAIL DISEASE; NAUSEA; NEPHROGENIC DIABETES INSIPIDUS; NEPHROLITHIASIS; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PANCREATITIS; PERIPHERAL NEUROPATHY; PR INTERVAL; PRACTICE GUIDELINE; PREGNANT WOMAN; REVIEW; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TERATOGENICITY; THAILAND; TOXIC EPIDERMAL NECROLYSIS; TREATMENT FAILURE; TREATMENT INDICATION; VIRUS LOAD; VOMITING; WEAKNESS;

EID: 77955263111     PISSN: 19057415     EISSN: None     Source Type: Journal    
DOI: 10.2478/abm-2010-0066     Document Type: Review

References (71)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338:853-60.
2. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ. 1997; 315:1194-9.
3. Sungkanuparph S, Kiertiburanakul S, Manosuthi W, Kiatatchasai W, Vibhagool A. Initiation of highly active antiretroviral therapy in advanced AIDS with CD4
4. Kiertiburanakul S, Sungkanuparph S, Rattanasiri S, Manosuthi W, Vibhagool A, Thakkinstian A. Virological and immunological responses of efavirenz-based HAART regimen initiated in HIV-infected patients at CD4 or = 100 cells/mm3. J Med Assoc Thai. 2006; 89:1381-7.
5. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006; 43:42-6.
6. Jongwutiwes U, Kiertiburanakul S, Sungkanuparph S. Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr HIV Res. 2007; 5: 355-60.
7. Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai. 2004; 87:760-7.
8. Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P, Krudsood S, Pitisuttithum P. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+ nevirapine) in treatment-naive adult HIV patients. Southeast Asian J Trop Med Public Health. 2005; 36: 362-9.
9. Chasombat S, Lertpiriyasuwat C, Thanprasertsuk S, Suebsaeng L, Lo YR. The National Access to Antiretroviral Program for PHA (NAPHA) in Thailand. Southeast Asian J Trop Med Public Health. 2006; 37: 704-15.
10. Sungkanuparph S, Anekthananon T, Hiransuthikul N, Bowonwatanuwong C, Supparatpinyo K, Mootsikapun P, et al; Thai AIDS Society. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai. 2008; 1:925-35.
11. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. Available at http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. Accessed 11 April 2010.
12. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents-November 2009; 1-24. Available at http://www.who.int/ HIV/pub/arv/rapid-advice-art.pdf. Accessed 11 April 2010.
13. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect. 2006; 53:357-63.
14. Sungkanuparph S, Jongwutiwes U, Kiertiburanakul S. Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis. J Acquir Immune Defic Syndr. 2007; 45:595-6.
15. Sungkanuparph S, Vibhagool A, Manosuthi W, Kiertiburanakul S, Atamasirikul K, Aumkhyan A, Thakkinstian A. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study. J Med Assoc Thai. 2004; 87: 1349-54.
16. Sungkanuparph S, Wongprasit P, Manosuthi W, Atamasirikul K. Compliance with hepatitis B and hepatitis C virus infection screening among HIV-1 infected patients in a resource-limited setting. Southeast Asian J Trop Med Public Health. 2008; 39: 863-6.
17. Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, et al. UK Collaborative HIV Cohort (CHIC) Study. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet. 2007; 370:1923-8.
18. de Beaudrap P, Etard JF, Gu ye FN, Gu ye M, Landman R, Girard PM, et al; ANRS 1215/1290 Study Group. Long-term efficacy and tolerance of efavirenz-and nevirapine-containing regimens in adult HIV type 1 Senegalese patients. AIDS Res Hum Retroviruses. 2008; 24:753-60.
19. Egger S, Petoumenos K, Kamarulzaman A, Hoy J, Sungkanuparph S, Chuah J, et al; Asia Pacific HIV Observational Database (APHOD). Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr. 2009; 50: 513-20.
20. Sungkanuparph S, Chakriyanuyok T, Butthum B. Antiretroviral therapy in AIDS patients with CMV disease: impact on the survival and long-term treatment outcome. J Infect. 2008; 56:40-3.
21. Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, et al; Staccato Thailand Study Group. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther. 2008; 13:375-80.
22. Duncombe C, Kerr SJ, Ruxrungtham K, Dore GJ, Law MG Emery S, et al. HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. AIDS. 2005; 19:169-78.
23. Lohse N, Hansen AB, Pedersen G Kronborg G Gerstoft J, S rensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007; 146:87-95.
24. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41(RR-17):1-19.
25. Supparatpinyo K, Chiewchanvit S, Hirunsri P, Uthammachai C, Nelson KE, Sirisanthana T. Penicillium marneffei infection in patients infected with human immunodeficiency virus. Clin Infect Dis. 1992; 14: 871-4.
26. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009; 4:e5575.
27. Sterne JA, May M, Costagliola D, de Wolf F, Phillips A, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009; 373:1352-63.
28. Baker JV, Peng G Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008; 22:841-8.
29. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008; 197:1133-44.
30. Severe P, Pape J, Fitzgerald DW A randomized clinical trial of early versus standard antiretroviral therapy for HIV-infected patients with a CD4 T cell count of 200-350 cells/mL (CIPRAHT001). Presented at the 46th ICAAC, San Francisco, September, 2009 (Abstract H-1230c).
31. Chaiwarith R, Salee P, Kotarathitithum W, Sirisanthana T, Supparatpinyo K. Long-term CD4 cell count recovery among Thai naive HIV-infected patients initiating HAART at low CD4 cell count. Curr HIV Res. 2009; 7: 340-5.
32. Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A. Nevirapine-versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. HIV Med. 2004; 5:105-9.
33. Chuapai Y, Kiertiburanakul S, Malathum K, Sungkanuparph S. Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy. J Med Assoc Thai. 2007; 90:452-8.
34. Puttawong S, Prasithsirikul W, Vadcharavivad S. Prevalence of lipodystrophy in Thai-HIV infected patients. J Med Assoc Thai. 2004; 87:605-11.
35. Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS. 2005; 19: 1481-6.
36. Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, Prasithsirikul W, Inthong Y, Phoorisri T, Sungkanuparph S. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis. 2006; 43: 253-5.
37. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010; 362:697-706.
38. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Vibhagool A. Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand. J Infect. 2006; 52:188-94.
39. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, Ruxrungtham K, Vibhagool A, Rattanasiri S, Thakkinstian A. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS. 2006; 20: 131-2.
40. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, et al; N2R Study Team. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis. 2009; 48:1752-9.
41. Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis. 2007; 44:141-4.
42. Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Yamada N, et al. Pharmacokinetics and 48 weeks efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-Tuberculosis co-infection receiving rifampicin. Antivir Ther. 2008; 13: 529-36.
43. Hammer SM, Saag MS, Schechter M, Montaner JSG, Schooley RT, Jacobsen DM, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA. 2008; 300:555-70.
44. Raboud JM, Rae S, Hogg RS, Yip B, Sherlock CH, Harrigan PR, et al. Suppression of plasma viral load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. J Infect Dis. 1999;180:1347-50.
45. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003; 163:2187-95.
46. Mee P, Fielding KL, Charalambous S, Churchyard GL, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008; 22:1971-7.
47. Badri M, Lawn SD, Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis. 2008; 8:89.
48. Kantor R, Diero L, Delong A, Kamle L, Muyonga S, Mambo F, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009; 49:454-62.
49. Nuesch R, Srasuebkul P, Ananworanich J, Ruxrungtham K, Phanuphak P, Duncomb C. HIV-NAT Study Team. Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. J Antimicrob Chemother. 2006; 58:637-44.
50. Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, Malathum K, Sathapatayavongs B. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen. Int J STD AIDS. 2007; 18:832-4.
51. Homsanit M, Nelson KE, Sonjai A, Anekthananon T, Suwanagool S, Cofrancesco J Jr. Body shape and metabolic abnormalities in Thai HIV-infected patients. AIDS Res Hum Retroviruses. 2007; 23:1314-21.
52. Hiransuthikul N, Hiransuthikul P, Kanasook Y. Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors. Southeast Asian J Trop Med Public Health. 2007; 38:69-77.
53. Ananworanich J, Nuesch R, Cot? HC, Kerr SJ, Hill A, Jupimai T, Laopraynak N, et al. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine-a Staccato trial substudy. J Antimicrob Chemother. 2008; 61:1340-3.
54. Kerr SJ, Duncombe C, Avihingsanon A, Ananworanich J, Boyd M, Sopa B, et al. Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. J Int Assoc Physicians AIDS Care (Chic Ill). 2007; 6:36-46.
55. Sungkanuparph S, Vibhagool A, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C. Opportunistic infections after the initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with a high prevalence of tuberculosis. AIDS. 2003; 17:2129-31.
56. Manosuthi W, Chaovavanich A, Tansuphaswadikul S, Prasithsirikul W, Inthong Y, Chottanapund S, et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting. J Infect. 2007; 55:464-9.
57. Sungkanuparph S, Filler SG, Chetchotisakd P, Pappas PG, Nolen TL, Manosuthi W, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis. 2009; 49:931-4.
58. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M; IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010; 10: 251-61.
59. Marais S, Wilkinson RJ, Pepper DJ, Meintjes G. Management of patients with the immune reconstitution inflammatory syndrome. Curr HIV AIDS Rep. 2009; 6:162-71.
60. Chaiwarith R, Wachirakaphan C, Kotarathititum W, Praparatanaphan J, Sirisanthana T, Supparatpinyo K. Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. Int J Infect Dis. 2007; 11: 413-6.
61. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of Stavudine, Lamivudine, and Nevirapine fails. Clin Infect Dis. 2007; 44:447-52.
62. Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005; 40:404-12.
63. Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S, Sutthent R, Anekthananon T, Bowonwatanuwong C, et al. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. J Int Assoc Physicians AIDS Care (Chic Ill). 2006; 5:152-6.
64. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J Clin Virol. 2008; 41:310-3.
65. Palella FJ Jr, Armon C, Buchacz K, Cole SR, Chmiel JS, Novak RM, et al; HOPS (HIV Outpatient Study) Investigators. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2009; 151:73-84.
66. Walmsley SL, Katlama C, Lazzarin A, Arest h K Pierone G, Blick G et al. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). J Acquir Immune Defic Syndr. 2008; 47: 429-40.
67. Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C. Study Team. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir +saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. HIV Med. 2007; 8: 529-35.
68. van der Lugt J, Autar RS, Ubolyam S, Garcia EF, Sankote J, Avihingson A, et al. HIV-NAT 019 Study Team. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. J Antimicrob Chemother. 2008; 61:1145-53.
69. Manosuthi W. Sungkanuparph S. Ruxrungtham K. Prasithsirikul W. Athichathanabadi C. Tantisiriwat W. et al. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir J Acquir Immune Defic Syndr 2008 47 127-129
70. Manosuthi W, Sungkanuparph S, Ruxrungtham K, Prasithsirikul W, Athichathanabadi C, Tantisiriwat W, et al. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr. 2008; 47:127-9. 70. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009; 17:138-45.
71. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO Trial. Clin Infect Dis. 2009; 49: 1441-9.